Correction: Targeted Oncology 10.1007/s11523-022-00893-y
The co-author name incorrectly published as Homer Adams III should read as Homer C. Adams III.
The original article has been corrected.
. 2022 Aug 1;17(5):609. doi: 10.1007/s11523-022-00904-y
Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
Suzette Girgis
1,✉, Shun Xin Wang Lin
2, Kodandaram Pillarisetti
2, Arnob Banerjee
2, Tara Stephenson
2, Xuewen Ma
2, Shoba Shetty
2, Tong-Yuan Yang
2, Brandi W Hilder
2, Qun Jiao
2, Brett Hanna
2, Homer C Adams III
2, Yu-Nien Sun
2, Amarnath Sharma
3, Jennifer Smit
2, Jeffrey R Infante
1, Jenna D Goldberg
1, Yusri Elsayed
2
Suzette Girgis
1Janssen Research & Development, 920 Route 202, Raritan, NJ 08869 USA
Find articles by Suzette Girgis
Shun Xin Wang Lin
2Janssen Research & Development, Spring House, PA USA
Find articles by Shun Xin Wang Lin
Kodandaram Pillarisetti
2Janssen Research & Development, Spring House, PA USA
Find articles by Kodandaram Pillarisetti
Arnob Banerjee
2Janssen Research & Development, Spring House, PA USA
Find articles by Arnob Banerjee
Tara Stephenson
2Janssen Research & Development, Spring House, PA USA
Find articles by Tara Stephenson
Tong-Yuan Yang
2Janssen Research & Development, Spring House, PA USA
Find articles by Tong-Yuan Yang
Brandi W Hilder
2Janssen Research & Development, Spring House, PA USA
Find articles by Brandi W Hilder
Homer C Adams III
2Janssen Research & Development, Spring House, PA USA
Find articles by Homer C Adams III
Jeffrey R Infante
1Janssen Research & Development, 920 Route 202, Raritan, NJ 08869 USA
Find articles by Jeffrey R Infante
Jenna D Goldberg
1Janssen Research & Development, 920 Route 202, Raritan, NJ 08869 USA
Find articles by Jenna D Goldberg
1Janssen Research & Development, 920 Route 202, Raritan, NJ 08869 USA
2Janssen Research & Development, Spring House, PA USA
3Janssen Research & Development, Tokyo, Japan
✉
Corresponding author.
Issue date 2022.
© The Author(s) 2022
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
PMCID: PMC9512742 PMID: 35913648
This corrects the article "Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma" on page 433.